On October 12, Twist Bioscience Corp fell 5.44% in regular trading, trading at $150.895/share, with Turnover of $120 million. The decline extends the stock's recent weakness as markets continue to digest valuation divergence in the synthetic DNA sector.

The primary catalyst remains Jefferies' initiation of coverage with a Hold rating and a $150 price target. While this target provided a temporary anchor on October 9, when the stock rallied over 5%, it offers no meaningful upside from current levels and has failed to sustain buying interest. The stock had already dropped 5.63% on October 8 amid broader biotech sector weakness, and today's decline suggests lingering uncertainty around near-term growth expectations for synthetic DNA applications in healthcare, food/agriculture, and data storage.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products, including synthetic genes, oligo pools, NGS tools, and antibody optimization solutions for biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs. The company is headquartered in South San Francisco, California.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)